Inovio Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones11-04 06:24

DJ Inovio Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Inovio Pharmaceuticals Inc. $(INO)$ plunged 12.17% to $1.66 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 0.83% to 25,372.01 and the Dow Jones Industrial Average falling 0.38% to 51,786.72.

Inovio Pharmaceuticals Inc. closed 38.97% short of its 52-week high of $2.72, which the company achieved on December 17th.

The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson $(JNJ)$ fell 1.62% to $266.17, Statera Biopharma Inc. (STAB) remained unchanged, and Pfizer Inc. $(PFE)$ fell 2.18% to $30.00.

Trading volume (42.8 M) eclipsed its 50-day average volume of 9.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 3, 2026.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment